Georg Wensing

3.3k total citations · 2 hit papers
73 papers, 2.6k citations indexed

About

Georg Wensing is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Georg Wensing has authored 73 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Physiology. Recurrent topics in Georg Wensing's work include Pulmonary Hypertension Research and Treatments (12 papers), Liver Disease and Transplantation (10 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Georg Wensing is often cited by papers focused on Pulmonary Hypertension Research and Treatments (12 papers), Liver Disease and Transplantation (10 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Georg Wensing collaborates with scholars based in Germany, United States and Netherlands. Georg Wensing's co-authors include Barbara Voith, Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf, Wolfgang Mück, Reiner Frey, Sigrun Unger, Gerrit Weimann, Robert A. Branch and G. Rohde and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Georg Wensing

68 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

2005 512 citations Dagmar Kubitza, Michael Becka et al. Clinical Pharmacology & Therapeutics profile →
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

2005 507 citations Dagmar Kubitza, Michael Becka et al. European Journal of Clinical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Georg Wensing Germany	22	1.4k	814	463	279	279	73	2.6k
Victor Dishy United States	23	878 0.6×	351 0.4×	180 0.4×	370 1.3×	207 0.7×	48	1.8k
Victor L. Serebruany United States	33	2.8k 2.0×	783 1.0×	219 0.5×	234 0.8×	1.2k 4.3×	114	3.8k
Lutz Binder Germany	31	1.8k 1.2×	604 0.7×	289 0.6×	393 1.4×	303 1.1×	86	3.3k
Gary Peters United States	27	2.1k 1.5×	1.2k 1.5×	108 0.2×	275 1.0×	925 3.3×	67	3.4k
Shashank Rohatagi United States	27	706 0.5×	326 0.4×	587 1.3×	202 0.7×	177 0.6×	83	2.2k
Zhimin Wang China	24	1.2k 0.8×	273 0.3×	721 1.6×	444 1.6×	318 1.1×	127	3.0k
Giulia Renda Italy	27	1.9k 1.3×	350 0.4×	186 0.4×	539 1.9×	746 2.7×	111	3.5k
Robert J. Noveck United States	27	499 0.3×	245 0.3×	161 0.3×	229 0.8×	294 1.1×	70	2.0k
Nita A. Limdi United States	25	795 0.6×	267 0.3×	105 0.2×	369 1.3×	214 0.8×	94	2.4k
C. Steven Ernest United States	22	1.4k 0.9×	311 0.4×	113 0.2×	97 0.3×	662 2.4×	41	2.1k

Countries citing papers authored by Georg Wensing

Since Specialization

Citations

This map shows the geographic impact of Georg Wensing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Wensing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Wensing more than expected).

Fields of papers citing papers by Georg Wensing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Wensing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Wensing. The network helps show where Georg Wensing may publish in the future.

Co-authorship network of co-authors of Georg Wensing

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Wensing. A scholar is included among the top collaborators of Georg Wensing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Wensing. Georg Wensing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coch, Christoph, Martin Coenen, Frank Donath, et al.. (2017). Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials. European Journal of Clinical Pharmacology. 73(4). 409–416. 16 indexed citations

Frey, Reiner, Michaël Reber, Jörn Krätzschmar, et al.. (2016). Riociguat (BAY 63‐2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study. Pulmonary Circulation. 6(S1). S35–42. 11 indexed citations

Frey, Reiner, Corina Becker, Sigrun Unger, et al.. (2016). Assessment of the Effects of Hepatic Impairment and Smoking on the Pharmacokinetics of a Single Oral Dose of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63‐2521). Pulmonary Circulation. 6(S1). 25 indexed citations

Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations. European Respiratory Journal. 44(Suppl 58). P1511–P1511. 2 indexed citations

Nagelschmitz, Johannes, et al.. (2014). The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects. European Respiratory Journal. 44(Suppl 58). P1510–P1510. 2 indexed citations

Nagelschmitz, Johannes, et al.. (2014). Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clinical Pharmacology Advances and Applications. 6. 51–51. 98 indexed citations

Lentini, Silvia, Nina Kimmeskamp‐Kirschbaum, Georg Wensing, & Roland Heinig. (2012). Abstract 10732: BAY 94-8862 Exerts a Potent Natriuretic Effect in Healthy Male Subjects Pre-treated With Fludrocortisone: Findings From a Proof-of-concept Study. Circulation. 126. 4 indexed citations

Frey, Reiner, et al.. (2010). Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study. The Journal of Clinical Pharmacology. 51(7). 1051–1060. 41 indexed citations

Guenther, Ulf, Hermann Wrigge, Nils Theuerkauf, et al.. (2010). Repinotan, a Selective 5-HT1A-R-Agonist, Antagonizes Morphine-Induced Ventilatory Depression in Anesthetized Rats. Anesthesia & Analgesia. 111(4). 901–907. 21 indexed citations

10.

Grimminger, Friedrich, Gerrit Weimann, R Frey, et al.. (2009). First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. European Respiratory Journal. 33(4). 785–792. 188 indexed citations

11.

Frey, Reiner, et al.. (2008). Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58‐2667) in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 48(12). 1400–1410. 56 indexed citations

12.

Wensing, Georg, et al.. (2007). Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63–9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties. European Journal of Clinical Pharmacology. 63(12). 1123–1128. 4 indexed citations

13.

Kuhlmann, J. & Georg Wensing. (2006). The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes. Current Clinical Pharmacology. 1(2). 185–191. 25 indexed citations

14.

Kuhlmann, J., et al.. (2005). Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects. International Journal of Clinical Pharmacology and Therapeutics. 43(5). 217–226. 32 indexed citations

15.

Kubitza, Dagmar, Michael Becka, Barbara Voith, Michael Zuehlsdorf, & Georg Wensing. (2005). Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical Pharmacology & Therapeutics. 78(4). 412–421. 512 indexed citations breakdown →

16.

Haase, Claus G., Michael Becka, J. Kuhlmann, & Georg Wensing. (2005). Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29(4). 549–556. 6 indexed citations

17.

Kubitza, Dagmar, Michael Becka, Georg Wensing, Barbara Voith, & Michael Zuehlsdorf. (2003). Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood. 102(11). 811. 19 indexed citations

18.

Kügler, Christian, A. Taghavy, E. Lotterer, et al.. (1994). Dynamics of cognitive brain dysfunction in patients with cirrhotic liver disease: an event-related P300 potential perspective. Electroencephalography and Clinical Neurophysiology. 91(1). 33–41. 16 indexed citations

19.

Wensing, Georg, et al.. (1994). Effect of BAY x7195, an oral receptor antagonist of cysteinyl-leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers. European Journal of Clinical Pharmacology. 47(3). 227–230. 2 indexed citations

20.

Wensing, Georg, Heiner Mönig, E. E. Ohnhaus, & H. Hoensch. (1991). Pharmacokinetics of encainide in patients with cirrhosis. Cardiovascular Drugs and Therapy. 5(4). 733–739. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact